E-Z-EM introduces new GI contrast agent

Article

Contrast agent developer E-Z-EM launched a new contrast agent at December’s RSNA show. Digibar 190 is a barium sulfate product for use in digital fluoroscopic studies of the gastrointestinal tract, and is first in a line of contrast media products

Contrast agent developer E-Z-EM launched a new contrast agent at December’s RSNA show. Digibar 190 is a barium sulfate product for use in digital fluoroscopic studies of the gastrointestinal tract, and is first in a line of contrast media products E-Z-EM is developing for digital imaging systems. Also at the show, the company’s subsidiary, AngioDynamics, unveiled three new products, including a fluid drainage catheter, a balloon catheter, and a biliary stent. Queensbury, NY-based AngioDynamics has already begun U.S. sales of its fluid drainage catheter, called Abscession. Its new balloon catheter, WorkHorse, and its Vistaflex platinum biliary stent have been cleared by the Food and Drug Administration, and the company expected to begin selling the products in December.

In other E-Z-EM news, the Westbury, NY, firm reported second-quarter 2000 results (end-November), with earnings of $1.8 million, compared with 1999’s $1.5 million. E-Z-EM posted sales of $28 million for the quarter, up from the previous year’s $26.5 million.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.